Contrasting Envoy Medical (NASDAQ:COCH) & Artivion (NYSE:AORT)

Envoy Medical (NASDAQ:COCH) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares Envoy Medical and Artivion”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$240,000.00	214.94	-$23.76 million	($1.01)	-0.66
Artivion	$441.33 million	2.80	$9.77 million	$0.24	106.00

Artivion has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Envoy Medical has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Insider and Institutional Ownership

8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 7.1% of Envoy Medical shares are owned by insiders. Comparatively, 6.3% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Envoy Medical and Artivion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-9,875.64%	N/A	-177.92%
Artivion	2.55%	7.15%	3.63%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Envoy Medical and Artivion, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1	1	1	0	2.00
Artivion	1	0	7	0	2.75

Envoy Medical currently has a consensus target price of $2.50, indicating a potential upside of 272.58%. Artivion has a consensus target price of $44.17, indicating a potential upside of 73.61%. Given Envoy Medical’s higher possible upside, equities analysts clearly believe Envoy Medical is more favorable than Artivion.

Summary

Artivion beats Envoy Medical on 10 of the 14 factors compared between the two stocks.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.